Related Experiment Video
Updated: Jun 15, 2026
07:25
Lipid Supplementation for Longevity and Gene Transcriptional Analysis in Caenorhabditis elegans
Published on: December 9, 2022
Cholesteryl ester transfer protein gene polymorphisms and longevity syndrome
Genovefa Kolovou1, Marianna Stamatelatou, Katherine Anagnostopoulou
11st Cardiology Department, Onassis Cardiac Surgery Center Athens, Greece.
The Open Cardiovascular Medicine Journal
|March 5, 2010
Summary
Genetic variants in cholesteryl ester transfer protein (CETP) may be linked to longevity syndrome (LS), characterized by high HDL cholesterol. The TaqIB B2 allele was more frequent in LS individuals, suggesting a genetic component to this longevity trait.
Area of Science:
- Cardiovascular Genetics
- Lipid Metabolism
- Longevity Research
Background:
- High-density lipoprotein (HDL) cholesterol is inversely correlated with coronary heart disease (CHD) risk.
- Longevity syndrome (LS) may be characterized by elevated HDL and low-density lipoprotein (LDL) cholesterol levels.
- Cholesteryl ester transfer protein (CETP) influences HDL particle composition and function.
Purpose of the Study:
- To investigate the association between two cholesteryl ester transfer protein (CETP) gene polymorphisms (TaqIB and I405V) and longevity syndrome (LS).
- To determine if specific CETP genotypes contribute to the development of LS, a state of high HDL cholesterol.
Main Methods:
- A case-control study involving 136 unrelated individuals without a history of CHD.
- Participants were categorized into LS (n=69) and non-LS (n=67) groups based on HDL cholesterol levels.
- Genotyping was performed for TaqIB and I405V polymorphisms within the CETP gene.
Main Results:
- The frequency of the B2 allele for the TaqIB polymorphism was significantly higher in the LS group compared to the non-LS group (p=0.03).
- Conversely, the B1 allele frequency was higher in the non-LS group (p=0.03).
Conclusions:
- CETP gene polymorphisms, specifically TaqIB, may be associated with longevity syndrome.
- Favorable gene polymorphisms, in conjunction with very high HDL cholesterol, could be prerequisites for LS.
- Further research with larger cohorts and additional genetic markers is warranted to confirm these findings.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...